GS
BEAM icon

GTS Securities’s Beam Therapeutics BEAM Stock Holding History

GTS Securities’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$232K Buy
+9,755
New +$271K 0.01% 1268
2025
Q4 		– Sell
-23,032
Closed -$559K – 1398
2025
Q3 		$559K Buy
+23,032
New +$458K 0.02% 672

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

GTS Securities's BEAM Position: Q1 2026 in Review

GTS Securities opened a new position in Beam Therapeutics (BEAM) in Q1 2026: 9,755 shares worth $232K. The stake represents 0.01% of the portfolio and ranks #1268 among its holdings. This is a return to the name: GTS Securities previously reported a position in BEAM as recently as Q3 2025.

GTS Securities first reported a position in BEAM in Q3 2025 and has held it in 2 quarters since. The position peaked at $559K in Q3 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • GTS Securities held 9,755 shares of Beam Therapeutics worth $232K as of Q1 2026.
  • Beam Therapeutics was a new GTS Securities position in Q1 2026.
  • Beam Therapeutics made up 0.01% of GTS Securities's portfolio in Q1 2026, its #1268 holding.
  • GTS Securities first reported a position in Beam Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • GTS Securities's Beam Therapeutics position peaked at $559K in Q3 2025.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.